Adaptive Biotechnologies Statistics
Want to see ADPT full AI Analyst Report?
Adaptive Biotechnologies (ADPT) Stock Statistics & Valuation Metrics
Total Valuation
Adaptive Biotechnologies has a market cap or net worth of $4.75B. The enterprise value is $5.52B.
- Market Cap
- $4.75B
- Enterprise Value
- $5.52B
Share Statistics
Adaptive Biotechnologies has 161,876,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 161,876,700
- Owned by Insiders
- 2.92%
- Owned by Institutions
- 41.75%
Financial Efficiency
Adaptive Biotechnologies’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -13.09%.
- Return on Equity (ROE)
- -0.27
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -13.09%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 443.87K
- Profits Per Employee
- -95.35K
- Employee Count
- 624
- Asset Turnover
- 0.54
- Inventory Turnover
- 7.27
Valuation Ratios
The current PE Ratio of Adaptive Biotechnologies is -66.53. Adaptive Biotechnologies’s PEG ratio is -57.49.
- PE Ratio
- -66.53
- PS Ratio
- 16.26
- PB Ratio
- 27.25
- Price to FCF
- -549.38
- Price to Operating Cash Flow
- -1122.84
- PEG Ratio
- -57.49
Income Statement
In the last 12 months, Adaptive Biotechnologies had revenue of 276.98M and earned -59.50M in profits. Earnings per share was -0.39.
- Revenue
- 276.98M
- Gross Profit
- 205.62M
- Operating Income
- -57.12M
- Pretax Income
- -59.46M
- Net Income
- -59.50M
- EBITDA
- -29.85M
- Earnings Per Share (EPS)
- -0.39
Cash Flow
In the last 12 months, operating cash flow was -4.28M and capital expenditures -4.54M, giving a free cash flow of -8.82M billion.
- Operating Cash Flow
- -4.28M
- Free Cash Flow
- -8.82M
- Free Cash Flow per Share
- -0.05
Dividends & Yields
Adaptive Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.18%
- Earnings Yield
- -1.46%
Stock Price Statistics
- Beta
- 1.15
- 52-Week Price Change
- 106.06%
- 50-Day Moving Average
- 26.40
- 200-Day Moving Average
- 19.82
- Relative Strength Index (RSI)
- 62.12
- Average Volume (3m)
- 2.18M
Important Dates
Adaptive Biotechnologies upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Adaptive Biotechnologies as a current ratio of 3.34, with Debt / Equity ratio of 128.24%
- Current Ratio
- 3.34
- Quick Ratio
- 3.23
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- -7.04
- Interest Coverage Ratio
- -4.85
Taxes
In the past 12 months, Adaptive Biotechnologies has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Adaptive Biotechnologies EV to EBITDA ratio is -175.16, with an EV/FCF ratio of -590.37.
- EV to Sales
- 17.48
- EV to EBITDA
- -175.16
- EV to Free Cash Flow
- -590.37
- EV to Operating Cash Flow
- -1217.74
Balance Sheet
Adaptive Biotechnologies has $298.95M in cash and marketable securities with $408.97M in debt, giving a net cash position of -$110.02M billion.
- Cash & Marketable Securities
- $298.95M
- Total Debt
- $408.97M
- Net Cash
- -$110.02M
- Net Cash Per Share
- -$0.68
- Tangible Book Value Per Share
- $0.40
Margins
Gross margin is 74.01%, with operating margin of -16.18%, and net profit margin of -23.66%.
- Gross Margin
- 74.01%
- Operating Margin
- -16.18%
- Pretax Margin
- -23.74%
- Net Profit Margin
- -23.66%
- EBITDA Margin
- -9.98%
- EBIT Margin
- -15.12%
Analyst Forecast
The average price target for Adaptive Biotechnologies is $33.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $33.43
- Price Target Upside
- 11.65% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- 17.91%
- EPS Growth Forecast
- 16.01%
Scores
- Smart Score
- 9
- AI Score
- 57
